Charles River Laboratories International, Inc.· CRL

🇺🇸 US · LargeSP500NYSE

Healthcare Medical - Diagnostics & Research Website

Price: $280.76
Day: -2.68%
Mkt Cap: $13.52B
52W Range: $144.26 – $303.31
Volume: 729.1K
Beta: 1.41

5D Framework

Company Overview

Snapshot of fundamentals, performance, and 5D scores.

5D scores: Quality 2.0, Peers 2.0, Valuation 1.0, Analysts 3.6, Holdings 2.4 (out of 5)
Market: $280.76 a share, market cap $13.52B, +73.3% over 12 months
Company: Healthcare · Medical - Diagnostics & Research, 19,000 employees, NYSE

Blog

Company Profile

Business fundamentals and company information

Business Description

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Key Details

CEO

Birgit Girshick

Employees

19,000

Headquarters

Wilmington, MA, US

IPO Date

Jun 2000

Exchange

New York Stock Exchange

Phone

781 222 6000

Healthcare · Medical - Diagnostics & Research

SEC filings

10-KFeb 18, 2026 10-QAug 5, 2026 8-KAug 5, 2026

Price Performance

Recent price action and historical returns

Price Performance

$280.76

Historical Returns

Price performance over time

1 Day

-2.68%

5 Day

-2.60%

1 Month

+4.96%

3 Months

+47.89%

6 Months

+67.75%

YTD

+40.75%

1 Year

+73.31%

3 Years

+40.56%

5 Years

-36.98%

10 Years

+250.16%

Revenue Analysis

How the business makes money, by product and geography

2025 revenue · 3 products

Revenue to Profit Flow · 2025

How revenue flows through the P&L: Products → Total Revenue → COGS → Gross Profit → operating costs (R&D, SG&A) → Operating Income → Tax / Interest → Net Income.

Learn how to read flow diagrams

5D Framework

Five lenses on the stock. Click any card to dive deeper.

Quality

Business fundamentals

2.0/5

Weak

View Details

Peers

Competitive position

2.0/5

Weak

View Details

Valuation

Model-based valuation (vs. price)

1.0/5

Well above estimate

View Details

Analysts

Wall Street sentiment

3.6/5

Bullish

View Details

Holdings

Smart money flows

2.4/5

Bearish

View Details

How to read these dimensions

The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.